{"id":5406,"date":"2026-04-22T12:26:05","date_gmt":"2026-04-22T16:26:05","guid":{"rendered":"https:\/\/www.bu.edu\/aodhealth\/?p=5406"},"modified":"2026-04-22T12:26:05","modified_gmt":"2026-04-22T16:26:05","slug":"nicotine-containing-e-cigarette-cessation-unaffected-by-cannabis-co-use-among-youth","status":"publish","type":"post","link":"https:\/\/www.bu.edu\/aodhealth\/2026\/04\/22\/nicotine-containing-e-cigarette-cessation-unaffected-by-cannabis-co-use-among-youth\/","title":{"rendered":"Nicotine-containing E-cigarette Cessation Unaffected by Cannabis Co-use Among Youth"},"content":{"rendered":"<p>Laboratory research suggests that nicotine and tetrahydrocannabinol (THC) may enhance one another\u2019s rewarding and dependence-related effects, raising concerns that cannabis use could interfere with nicotine cessation attempts. To clarify these relationships clinically among youth with nicotine-containing e-cigarette use, investigators conducted a secondary analysis of a single-site randomized controlled trial involving 261 participants aged 16\u201325 years. Participants were assigned to: 1) varenicline plus counseling; or 2) placebo plus counseling; or 3) enhanced usual care. At 12 weeks, nicotine-containing e-cigarette abstinence was assessed via self-report and verified with salivary cotinine testing. Investigators evaluated whether cannabis use frequency or cannabis use disorder (CUD) symptom severity affected nicotine cessation outcomes, and whether cannabis use moderated treatment effects of varenicline on nicotine vaping cessation.<\/p>\n<ul>\n<li>At baseline, 28 percent of participants reported no past-month cannabis use, 38 percent reported cannabis use more than 0 days and less than 4 days per week, and 30 percent reported cannabis use 4\u20137 days per week.<\/li>\n<li>Cannabis use frequency was not significantly associated with nicotine abstinence, nor did it affect varenicline\u2019s effectiveness for nicotine cessation.<\/li>\n<li>CUD symptom severity was not associated with nicotine abstinence, nor did it affect varenicline\u2019s effectiveness for nicotine vaping cessation.<\/li>\n<\/ul>\n<p><em>Comments:<\/em> These findings indicate that cannabis and nicotine co-use does not hinder nicotine cessation among youth, nor does it reduce the therapeutic benefits of varenicline. These results support offering patients standard nicotine cessation treatments\u2014including varenicline\u2014regardless of cannabis use.<\/p>\n<p>Susan L. Calcaterra, MD, MPH, MS<\/p>\n<p><em>Reference:<\/em> Gilman JM,\u00a0Cather C,\u00a0Reeder HT, et al. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385228\/\">Cannabis use and nicotine vaping cessation outcomes:\u00a0a secondary analysis of a randomized clinical trial<\/a>.\u00a0<em>JAMA Netw Open.<\/em>\u00a02025;8(12):e2547799.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Laboratory research suggests that nicotine and tetrahydrocannabinol (THC) may enhance one another\u2019s rewarding and dependence-related effects, raising concerns that cannabis use could interfere with nicotine cessation attempts. To clarify these relationships clinically among youth with nicotine-containing e-cigarette use, investigators conducted a secondary analysis of a single-site randomized controlled trial involving 261 participants aged 16\u201325 years. [&hellip;]<\/p>\n","protected":false},"author":11248,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[161],"tags":[77],"_links":{"self":[{"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/posts\/5406"}],"collection":[{"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/users\/11248"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/comments?post=5406"}],"version-history":[{"count":1,"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/posts\/5406\/revisions"}],"predecessor-version":[{"id":5407,"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/posts\/5406\/revisions\/5407"}],"wp:attachment":[{"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/media?parent=5406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/categories?post=5406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bu.edu\/aodhealth\/wp-json\/wp\/v2\/tags?post=5406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}